lncRNA small nucleolar RNA host gene 20 predicts poor prognosis in glioma and promotes cell proliferation by silencing P21

Figures & data

Table 1 Clinicopathological characteristics of patient samples and expression of lncRNA SNHG20 in glioma

Characteristics	No of cases (%)
Age (years)
<50	51 (47.2)
≥50	57 (52.8)
Gender
Female	52 (48.1)
Male	56 (51.9)
Tumor size (cm)
<5	58 (53.7)
≥5	50 (46.3)
Cystic change
Absence	61 (56.5)
Presence	47 (43.5)
KPS score
≥80	61 (56.5)
<80	47 (43.5)
Tumor location
Infratentorial	45 (41.7)
Supratentorial	63 (58.3)
Extent of resection
GTR	61 (56.5)
PR	47 (43.5)
WHO grade
I/II	43 (39.8)
III/IV	65 (60.2)
Follow-up time (months)	30.907±1.843
Survival status
Live	59 (54.6)
Death	49 (45.4)
Recurrence
Absence	52 (48.1)
Presence	56 (51.9)
Expression of lncRNA SNHG20
Low expression	54 (50.0)
High expression	54 (50.0)

Abbreviations: GTR, gross total resection; KPS, Karnofsky performance scale; PR, partial resection.

Figure 1 The lncRNA SNHG20 expression levels in glioma tissues are outstandingly higher than those in normal brain tissues.

Note: *P<0.05 means vs normal brain tissues.

Table 2 Association between lncRNA SNHG20 expression and clinicopathological characteristics of glioma patients

Characteristics	lncRNA SNHG20 expression		P-value
	Low, no of cases	High, no of cases
	Age (years)
<50	26	25	0.847
≥50	28	29
Gender
Female	24	28	0.441
Male	30	26
Tumor size (cm)
<5	37	21	0.002
≥5	17	33
Cystic change
Absence	33	28	0.332
Presence	21	26
KPS score
≥80	31	30	0.846
<80	23	24
Tumor location
Infratentorial	21	24	0.558
Supratentorial	33	30
Extent of resection
GTR	37	24	0.012
PR	17	30
WHO grade
I/II	27	16	0.031
III/IV	27	38
Follow-up time (months)	38.056±2.82	23.759±1.96		0.000
Survival status
Live	42	17	0.000
Death	12	37
Recurrence
Absence	36	16	0.000
Presence	18	38

Abbreviations: GTR, gross total resection; KPS, Karnofsky performance scale; PR, partial resection.

Table 3 Spearman analysis of correlation between lncRNA SNHG20 and clinicopathological

Variables	lncRNA SNHG20 expression level
	Spearman correlation	P-value
	Age (years)	0.019	0.849
Gender	−0.074	0.446
Tumor size	0.297	0.002
Cystic change	0.093	0.336
KPS score	0.019	0.848
Tumor location	−0.056	0.562
Extent of resection	0.243	0.011
WHO grade	0.208	0.031
Follow-up time	−0.343	0.000
Survival status	0.465	0.000
Recurrence	0.037	0.000

Abbreviation: KPS, Karnofsky performance scale.

Figure 2 Kaplan–Meier curves showing the survival of glioma patients with different lncRNA SNHG20 expression levels.

Notes: (A–E) OS curves stratified by lncRNA SNHG20 expression in total (A), low-grade (B), high-grade (C), small tumor size (D) and lager tumor size (E) glioma patients. (F–J) RFS curves stratified by lncRNA SNHG20 expression in total (F), low-grade (G), high-grade (H), small tumor size (I) and lager tumor size (J) glioma patients.

Abbreviations: OS, overall survival; RFS, recurrence-free survival.

Table 4 Univariate and multivariate analyses for overall survival in glioma patients

Variable	Univariate analysis			Multivariate analysis
	P-value	HR	95% CI	P-value	HR	95% CI
	Age (years) (<50 vs ≥50)	0.373	1.296	0.732–2.293	0.405	1.297	0.703–2.393
Gender (Female vs male)	0.512	1.208	0.686–2.129	0.742	0.892	0.450–1.766
Tumor size (<5 vs ≥5 cm)	0.000	2.899	1.627–5.165	0.111	1.676	0.889–3.163
Cystic change	0.001	2.686	1.500–4.810	0.002	2.833	1.489–5.390
KPS score	0.001	2.812	1.565–5.051	0.095	1.797	0.903–4.574
Tumor location	0.145	1.543	0.862–2.764	0.073	1.737	0.949–3.179
Extent of resection	0.014	2.025	1.151–3.564	0.965	1.015	0.529–1.948
WHO grade	0.001	3.077	1.629–5.810	0.008	2.669	1.286–5.542
Expression of lncRNA SNHG20	0.000	5.774	2.945–11.319	0.000	4.722	2.189–10.186

Abbreviation: KPS, Karnofsky performance scale.

Table 5 Univariate and multivariate analyses for recurrence-free survival in glioma patients

Variable	Univariate analysis			Multivariate analysis
	P-value	HR	95% CI	P-value	HR	95% CI
	Age (years)	0.340	1.298	0.760–2.215	0.460	1.239	0.703–2.184
Gender	0.237	1.384	0.808–2.371	0.421	1.281	0.701–2.340
Tumor size	0.000	2.872	1.663–4.959	0.042	1.87	1.023–3.418
Cystic change	0.011	2.028	1.176–3.499	0.045	1.791	1.014–3.165
KPS score	0.009	2.037	1.195–3.472	0.367	1.328	0.718–2.456
Tumor location	0.144	1.505	0.870–2.603	0.121	1.552	0.891–2.704
Extent of resection	0.011	1.985	1.170–3.367	0.600	1.169	0.653–2.092
WHO grade	0.003	2.366	1.344–4.163	0.053	1.858	0.993–3.480
Expression of lncRNA SNHG20	0.000	3.828	2.139–6.850	0.003	2.674	1.393–5.133

Abbreviation: KPS, Karnofsky performance scale.

Figure 3 SNHG20 siRNA is constructed, which can inhibit the lncRNA SNHG20 expression levels in glioma cells.

Notes: The knockdown efficiency of lncRNA SNHG20 is assessed by qRT-PCR. *P<0.05 means vs the NC siRNA group.

Abbreviation: qRT-PCR, quantitative real-time polymerase chain reaction.

Figure 4 lncRNA SNHG20 modulates the proliferation abilities of glioma U87 cells.

Notes: CCK-8 assays show that lncRNA SNHG20 suppression inhibits the proliferation of glioma U87 cells. *P<0.05 means vs the NC siRNA group.

Abbreviation: CCK-8, cell counting kit-8.

Figure 5 lncRNA SNHG20 modulates the colony formation abilities of glioma U87 cells.

Notes: Colony formation is dramatically reduced following SNHG20 silencing. *P<0.05 vs the NC siRNA group.

Figure 6 Flow cytometry of the cell cycle distribution of glioma U87 cells transfected with SNHG20 siRNA or NC siRNA.

Note: *P<0.05 vs the NC siRNA group.

Figure 7 lncRNA SNHG20 modulates the P21 (A–C) and CCNA1 (A, D, E) expression levels in glioma U87cells.

Note: *P<0.05 means vs the NC siRNA group.